We have a partnership-based business model as we generate and combine Nanofitins® for our partners on a target by target basis. We are looking for new partners for custom generation and combinations of Nanofitins® as next generation biopharmaceuticals.
More affinity with Affilogic ?
Contact : Mrs Nadège PREL
Director of Marketing & Business Development
Collaborative Research Programs
NanoModule: Affilogic is developing a new anti-cancer therapeutic approach, a multi-specific combination of nanofitins exhibiting anti-tumor activity, in partnership with the Western Cancer Institute (Institut de Cancérologie de l’Ouest, Saint-Herblain, France). It is possible to address multiple pathways of cancer with one poly functional molecule able to specifically reach and anchor on the tumour, recruit immune cells, reduce angiogenesis…This project was partially sponsored from January 2018 to December 2020 by a grant from the European Regional Development Fund (ERDF / FEDER) via the Region Pays de Loire.
OncoFitin Drug Conjugate: Affilogic is developing first-in-class vectors for targeted delivery of cytotoxic agents into cancer cells with its partners the Institute of Experimental Biology and Technology (Portugal) and the University of Geneva (Switzerland).This project was partially sponsored from November 2017 to February 2020 by a grant from Eurostars / the European Commission via BPI France (DOS0059903).
DiaSyn: Affilogic is collaborating with the University of Liège (Belgium), the University of Artois (France), UCB Biopharma (Belgium) and the Cajal Institute – Consejo Superior de Investigaciones Científicas (CSIC, Spain) under the framework of a EuroNanoMed program to develop a PET imaging tracer for highly specific detection and quantification of a Parkinson’s disease biomarker in the brain.
DiViNe: DiViNe will make a real-life demonstration of the concept of affinity chromatography for vaccines purification. This consortium is exactly structured with the requested elements of a value chain for design, development, validation and commercialization of custom downstream processing products, combined with the market understanding of a major end-user : Merck KGaA (Germany), GSK Vaccines (Italy), the Institute of Experimental Biology and Technology (Portugal), GenIbet Biopharmaceuticals (Portugal) and Aquaporin (Denmark).
NanoVax: Affilogic and its partners the Ghent University (Belgium), the Centre de recherches sur les macromolécules végétales (CNRS, France), the Oslo University Hospital (Norway) and the Institute for Bioengineering of Catalonia (Spain) are developing a novel class of potent and safe nanovaccines based on degradable nanoparticles conjugated to Nanofitins that target tumour associated antigens and activation stimuli to dendritic cells.